From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag
Open Access
- 1 February 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 8 (5), 159-174
- https://doi.org/10.1177/2040620717693573
Abstract
Thrombopoietin (TPO) is the most potent cytokine stimulating thrombopoiesis. Therapy with exogenous TPO is limited by the formation of antibodies cross-reacting with endogenous TPO. Mimetics of TPO are compounds with no antigenic similarity to TPO. Eltrombopag is an orally-active nonpeptide small molecule that binds to the transmembrane portion of the TPO receptor MPL. Initial trials of eltrombopag have centered on immune thrombocytopenia (ITP), which is due to both increased destruction and decreased production of platelets. Eltrombopag at 25–75 mg/day has been shown to be highly effective in raising the platelet count in ITP with suboptimal response to immunosuppression and splenectomy. These successful results led to the exploration of eltrombopag in other thrombocytopenic disorders. In hepatitis C viral infection, eltrombopag raises the platelet count sufficiently enough to allow treatment with ribavirin and pegylated interferon. Because MPL is expressed on hematopoietic cells, eltrombopag use in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) might enhance leukemic proliferation. Clinical trials of eltrombopag in MDS and AML, however, have shown amelioration of thrombocytopenia without promoting disease progression. In severe aplastic anemia (SAA) not responding to immunosuppression with anti-thymocyte globulin (ATG) and cyclosporine, eltrombopag as a single agent at 150–300 mg/day results in an overall response rate of 40–70%. At high doses, adverse effects including pigmentation, gastrointestinal upset and hepatic derangement have become evident. Current studies have examined the first-line use of eltrombopag in combination with ATG in SAA. In a recent study, eltrombopag used at 150 mg/day with horse ATG resulted in an overall response rate of 90% in newly diagnosed SAA patients, with a complete response rate of about 50%. Clonal karyotypic aberrations are, however, found in 10–20% of SAA patients treated with eltrombopag. The safety and efficacy of eltrombopag in SAA require further evaluation, particularly when it is used with less intensive immunosuppression.Keywords
This publication has 105 references indexed in Scilit:
- Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamideBMC Cancer, 2013
- Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumorsBMC Cancer, 2012
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaThe New England Journal of Medicine, 2012
- Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profileTherapeutic Advances in Hematology, 2012
- Thrombocytopenia in Adult Cancer Patients Receiving Cytotoxic ChemotherapyDrug Safety, 2011
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseHaematologica, 2010
- Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndromeBlood, 2009
- The potential role of thrombopoietin in idiopathic thrombocytopenic purpuraBlood Reviews, 2002
- Thrombopoietin induces activation of at least two distinct signaling pathwaysFEBS Letters, 1995
- Thrombopoietin Induces Tyrosine Phosphorylation and Activation of Mitogen-Activated Protein Kinases in a Human Thrombopoietin-Dependent Cell LineBiochemical and Biophysical Research Communications, 1995